September 27, 2016 3:22 AM ET


Company Overview of Shire Orphan Therapies GmbH

Company Overview

Shire Orphan Therapies GmbH discovers, develops, and commercializes peptide-based drugs for disease indications that have limited or no treatment options. The company offers Firazyr (Icatibant) for the treatment of acute attacks of hereditary angioedema in Germany, Austria, Spain, Greece, Denmark, Luxemburg, and the United Kingdom; and through named patient programs in France, Italy, Norway, and Belgium. Its developing product pipeline includes JSM 6427, a a5ß1 Integrin antagonist for the treatment of cancer, age-related macular degeneration-blindness in the elderly, and angiogenesis, inflammation, and fibrosis; and JSM-7717 and JPE-1375, which are C5a receptor antagonists for the treatment ...

Friedrichstrasse 149

Berlin,  10117


Founded in 1994

65 Employees


49 30 206 582 0


49 30 206 582 100

Key Executives for Shire Orphan Therapies GmbH

General Manager and Member of The Supervisory Board
Compensation as of Fiscal Year 2016.

Similar Private Companies By Industry

Company Name Region
3B Pharmaceuticals GmbH Europe
Accelsiors Group International Europe
Aenova Group GmbH Europe
Aenova Holding GmbH Europe
AiCuris GmbH & Co. KG Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Shire Orphan Therapies GmbH, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at